The randomized control clinical trial has become the gold standard scientific method for the evaluation of pharmaceuticals, biologics, devices, procedures and diagnostic tests. This trial design has been successfully used in both therapeutic and disease prevention trials. It is superior to alternative designs by eliminating several sources of bias which exist in those designs. This role has evolved over the past three decades in a number of disease areas including cardiology, opthalmology, cancer and AIDS. While the specifics of using the randomized control design for a specific intervention and disease may differ, the basic fundamentals still apply in developing the study protocol and operational procedures. These fundamentals still apply in developing the study protocol and operational procedures. These fundamentals include identifying the specific questions to be tested and appropriate outcome measures, determining an adequate sample size, specifying the randomization procedure, detailing the intervention with visit schedules for subject evaluation, establishing an interim data and safety monitoring plan, detailing the final analysis plan and determining the organizational structure. This text is structured to address the fundamentals as the protocol for a clinical trial is being developed. A chapter is devoted to each of the critical areas of a protocol to aid the clinical trial researcher. The fundamentals described in this text are based on sound scientific methodology, statistical principles and years of accumulated experience by the three authors. Collectively, the authors have been active researchers in a broad area of clinical trials including cardiology, cancer, opthalmology, diabetes, osteoporosis, AIDS, women's health and screening tests. In these studies, the authors have served as members of the steering committee responsible for developing the protocol and as members of data and safety monitoring committees. The fundamentals were proposed in the first edition published in 1981 and have not changed substantially in the later editions. However, the number of examples illustrating the fundamentals has greatly expanded base on the collective experience of the authors. This text is intended for the clinical researcher who is interested in designing a clinical trial and developing a protocol. It is also of value to researchers and practitioners who must critically evaluate the literature of published clinical trials and assess the merits of each trial and the implications for the care and treatment of patients. The test uses numerous examples of published clinical trials from a variety of medical disciples to meaningfully illustrate the fundamentals. Technical design issues such as sample size are considered but the technical details have been suppressed as much as possible through the use of graphs and tables. While the technical material has been kept to a minimum, the statistician may still find the principles and fundamentals presented in this text useful both in a consulting and teaching capacity. The text assumes that the readers have only a modest formal statistical background. A basic introductory statistics course is helpful in maximizing the benefit of the text. However, a researcher or practitioner with no statistical background would still find most, if not all the chapters understandable and useful.
评分
评分
评分
评分
我最近在追踪一些关于新型生物制剂在罕见病治疗中的最新临床路径和伦理考量,这本书的深度和广度在这方面表现得尤为出色。它并非停留在教科书式的理论堆砌,而是深入剖析了当前研究热点背后的驱动因素和潜在挑战。比如,其中关于适应性设计(Adaptive Designs)的章节,不仅详细介绍了数学模型和统计学原理,更结合了多个近期的真实案例,清晰地展示了如何在保证统计学严谨性的前提下,灵活调整试验方案以应对突发情况。这种理论与实践的无缝对接,让我对如何构建更高效、更具成本效益的试验方案有了豁然开朗的感觉。尤其是对于那些参与早期药物开发阶段的科研人员来说,这本书提供的策略性指导,远比单纯的指南手册来得更有价值和指导意义。它教会你“为什么”要这样做,而不仅仅是“应该”这样做。
评分坦白说,我对统计学背景的教材总是怀有一种天然的敬畏,很多书籍在涉及数据分析和样本量估算时,往往会陷入晦涩难懂的公式泥潭,让人望而却步。然而,这本书在处理这些复杂概念时,展现出一种令人称赞的教学天赋。它巧妙地运用了大量的流程图和类比说明,将那些原本高高在上的统计学名词“拉下神坛”,变得平易近人。举个例子,在解释安慰剂效应(Placebo Effect)的测量和控制时,作者没有直接抛出复杂的贝叶斯模型,而是先用一个清晰的场景故事引入,再逐步过渡到模型构建,这种层层递进的方式极大地降低了读者的学习曲线。对于临床医生或初级研究员而言,这本书提供了一个非常友好的“桥梁”,帮助他们跨越统计理解的鸿沟,真正自信地参与到试验方案的讨论和数据解读中去,而不是仅依赖统计师的报告。
评分这本书的结构安排极具逻辑性,仿佛是精心设计的一条探险路线图,引领读者从基础概念一步步深入到复杂的实战操作。开篇的模块为整个领域的建立起了一个坚实的基础,定义清晰、范围明确,使得后续内容的学习有了可靠的支撑点。接着,它流畅地过渡到试验设计的核心要素,如终点选择、剂量发现等关键环节,过渡自然到让人几乎察觉不到知识点的跳跃。而最精彩的部分在于,它没有止步于设计,而是详细地覆盖了数据管理、质量控制(QA/QC)以及最终报告撰写等“收尾”工作。这种“从摇篮到坟墓”的全流程覆盖,使得这本书不仅仅是一本参考手册,更像是一套完整的项目管理工作流程指南。它确保读者在阅读过程中,始终对整个试验的生命周期有一个宏观且精准的把握,避免了知识点的碎片化。
评分这本书的装帧设计简直是令人眼前一亮,硬壳封面的质感厚重而又不失典雅,那种微微泛着哑光的触感,握在手里就让人觉得这是一本沉甸甸的专业著作。我尤其欣赏它在细节处理上的用心,书脊的烫金字体清晰有力,即便是在昏暗的书房里也能一眼辨认出书名,这对于经常需要快速查找资料的人来说,简直是福音。内页的纸张选择也极度考究,米白色的纸张有效缓解了长时间阅读带来的视觉疲劳,而且油墨的印刷质量无可挑剔,图表和文字的边缘都锐利得如同刀刻,即使用高亮笔标记后,纸张也没有出现任何洇墨的现象。装订上,平摊后书页完全服帖,完全不必担心因为用力压平书脊而损伤书本,这极大地提升了阅读体验,让我愿意花更长的时间沉浸其中。这本书的物理形态本身,就传递出一种对知识的尊重和对读者的体贴,放在书架上也是一件赏心悦目的陈列品,完全体现了专业教材应有的水准和格调。
评分作为一名关注药物监管合规性的从业者,我发现本书在国际化标准和法规遵循这一块的论述,尤其具有前瞻性。它不仅仅罗列了FDA和EMA的现有要求,更深入探讨了全球数据共享协议(Data Sharing Agreements)的演变趋势,以及在跨文化背景下招募受试者时必须面对的伦理困境和解决方案。书中对ICH E6(R2)指南的解读,细致到每一个条款背后的设计哲学,而不是机械地背诵条文。最让我印象深刻的是关于药物警戒(Pharmacovigilance)的章节,它不仅仅讨论了不良事件的报告流程,还涵盖了真实世界证据(RWE)在上市后监测中的应用潜力,这明显是站在未来监管趋势前沿的视角。这本书的内容更新速度显然跟上了行业步伐,确保读者获取的知识是当下最前沿、最符合国际规范的。
评分读到怀疑人生。Clinical trial没有实操都是说扯蛋。而且RCT比cohort什么的要搞的东西多好多,还有各种ethical problems。感觉对付IRB,DSMB什么的有钱还是得外包。
评分读到怀疑人生。Clinical trial没有实操都是说扯蛋。而且RCT比cohort什么的要搞的东西多好多,还有各种ethical problems。感觉对付IRB,DSMB什么的有钱还是得外包。
评分textbook
评分读到怀疑人生。Clinical trial没有实操都是说扯蛋。而且RCT比cohort什么的要搞的东西多好多,还有各种ethical problems。感觉对付IRB,DSMB什么的有钱还是得外包。
评分textbook
本站所有内容均为互联网搜索引擎提供的公开搜索信息,本站不存储任何数据与内容,任何内容与数据均与本站无关,如有需要请联系相关搜索引擎包括但不限于百度,google,bing,sogou 等
© 2026 book.wenda123.org All Rights Reserved. 图书目录大全 版权所有